Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC trimmed its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.6% in the 4th quarter, HoldingsChannel reports. The firm owned 109,575 shares of the company’s stock after selling 6,500 shares during the period. Clear Harbor Asset Management LLC’s holdings in Teva Pharmaceutical Industries were worth $2,415,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Stifel Financial Corp grew its stake in shares of Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after purchasing an additional 23,283 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,218 shares during the period. Sio Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $24,314,000. CWA Asset Management Group LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $3,340,000. Finally, Two Sigma Advisers LP increased its holdings in shares of Teva Pharmaceutical Industries by 15.3% in the third quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock valued at $18,642,000 after purchasing an additional 137,000 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TEVA. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Barclays raised their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.13.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $21.97 on Tuesday. The company has a 50-day moving average of $19.33 and a 200-day moving average of $18.26. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a 12 month low of $10.86 and a 12 month high of $22.80.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.